Randomise Carboplatin AUC2 & Standard CRT Paclitaxel 80mg/m 2 - - PowerPoint PPT Presentation

▶

Feb 04, 2024 402 likes •467 views

INTERLACE Randomise Carboplatin AUC2 & Standard CRT Paclitaxel 80mg/m 2 Weeks 1-6 Standard CRT : 40 50.4Gy in 20-28 fractions plus Intracavitary brachytherapy to give total Weeks 7 13 EQD2 dose of 78-86Gy to point A/volume.

SLIDE 1

Randomise

Carboplatin AUC2 & Paclitaxel 80mg/m2

Weeks 1-6

Weeks 7 – 13 Standard CRT Standard CRT Follow-up 3 monthly for 2 years; 6 monthly for 3 years

Standard CRT : 40—50.4Gy in 20-28 fractions

plus Intracavitary brachytherapy to give total EQD2 dose of 78-86Gy to point A/volume. Weekly cisplatin 40mg/m2 x 5 weeks

INTERLACE

SLIDE 2

Eligibility criteria summary

All patients suitable for CRT, FIGO IB1 with +ve nodes-IVA

unless:

Nodes above aortic bifurcation
Disease involves lower third of vagina (FIGO IIIA)

IMRT permitted Recently received ethical approval for redesign of PIS and inclusion of a short series of patient accessible video links (via PIS) explaining the trial and featuring INTERLACE patient interviews.

INTERLACE

SLIDE 3

INTERLACE

2 4 6 8 10 12 14

Number of Patients/Sites

INTERLACE Trial - Total Monthly Accrual

Actual Monthy Accrual

SLIDE 4

INTERLACE

Current status Target recruitment – 770 Accrual to date (UK and Mexico) – 172 Number of sites open - 30

GICOM (Mexico) – 21 patients recruited since
pening in Feb 2016
MaNGO (Italy) – 5 sites in setup

SLIDE 5

INTERLACE

Contacts: Chief Investigator – Dr Mary McCormack mary.mccormack@uclh.nhs.uk RTQA – Yatman Tsang yatmantsang@nhs.net General Enquiries – ctc.interlace@ucl.ac.uk